- Recent Advances in Melanoma Therapy
- Targeted Treatments and Immunotherapies for Melanoma
- Tailoring Treatments in Melanoma
- Drug Resistance in Melanoma
- Affordability of Melanoma Care
- Melanoma: Treatment-induced Toxicity
- Immunotherapy: A Decade of Improvements in ...
- Should Patients With Melanoma Receive Targeted ...
- Melanoma: Checkpoints in the Pipeline
- Targeting Therapy for Melanoma Subtypes
- Melanoma: Targetable Genes in the Pipeline
- Clinical Trials in Melanoma
Skin Cancer News
First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
More Skin Cancer Information
All meta-analyses conducted to date show a significant association between indoor tanning use and an increased risk of melanoma or non-melanoma skin cancers.
Prevention and early detection are the best ways to keep your skin healthy.
This fact sheet offers tips to decrease the risk of malignant melanoma, the fastest growing forms of skin cancer.
This patient fact sheet provides patients with information on the causes of melanoma along with ways to protect against it and find support in the event of a diagnosis.
This patient fact sheet describes risk factors and preventative measures in skin cancer, malignant melanoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified